| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6339105 | JANSSEN PHARMS | Analgesic regimen |
Oct, 2019
(4 years ago) | |
|
US6339105 (Pediatric) | JANSSEN PHARMS | Analgesic regimen |
Apr, 2020
(4 years ago) | |
Ultram is owned by Janssen Pharms.
Ultram contains Tramadol Hydrochloride.
Ultram has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ultram are:
- US6339105
- US6339105*PED
Ultram was authorised for market use on 03 March, 1995.
Ultram is available in tablet;oral dosage forms.
Ultram can be used as a titration dosing regimen for the treatment of pain using an initial dose of about 25mg.
The generics of Ultram are possible to be released after 12 April, 2020.
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 03 March, 1995
Treatment: A titration dosing regimen for the treatment of pain using an initial dose of about 25mg
Dosage: TABLET;ORAL
How can I launch a generic of ULTRAM before it's drug patent expiration?
More Information on Dosage
ULTRAM family patents
